Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors

NCT07416123 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT07416123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1
Overall status
Recruiting
Start date
April 14, 2026
Completion date
June 25, 2029
Enrollment
103 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, urothelial carcinoma